ReNerve Expands Global Footprint with Strategic Partnership for Indian Market

Jane Morgan Management

Melbourne, Australia – 10 April 2025 | ReNerve Limited (ASX: RNV) (“ReNerve” or the “Company”), an Australian medical device company specialising in peripheral nerve repair technologies, is pleased to announce it has entered into a strategic partnership with NetCentrix Ventures to establish and expand its operations in the Indian healthcare market.

This agreement marks a key milestone in ReNerve’s global commercialisation strategy and supports the introduction of its flagship NervAlign® Nerve Cuff into one of the world’s fastest-growing medical device markets.

Highlights

• ReNerve partners with NetCentrix Ventures to secure regulatory approval and drive commercialisation of the NervAlign® Nerve Cuff in India.

• The Indian nerve repair market is currently valued at US$115 million and is forecast to grow at 18.5% CAGR, reaching over US$270 million by 2030.

• Partnership includes collaboration with BRIC RGCB, a key Indian government biomedical institute, to support validation and local approvals.

• India joins ReNerve’s growing list of international markets, alongside Taiwan, Hong Kong, the Middle East, and Mexico.

Strategic Opportunity in India

India represents a compelling expansion opportunity due to a combination of:

• Rapidly growing healthcare infrastructure.

• Increased demand for advanced surgical technologies.

• A rising middle class with improved access to specialist medical services.

• A high prevalence of traumatic nerve injuries and diabetes-related neuropathies.

• Development of microsurgical centres of excellence across major metropolitan regions.

This expansion initiative will initially focus on obtaining regulatory clearance for the NervAlign® Nerve Cuff, followed by a tailored commercialisation strategy designed for India’s evolving healthcare ecosystem​.

Commenting on the partnership, Dr. Julian Chick, CEO and Managing Director of ReNerve, stated: "India represents an exciting market opportunity in our global expansion strategy. The partnership with NetCentrix Ventures provides ReNerve with specialised local expertise and established distribution networks that are essential for a successful entry into an incredibly significant market. This Agreement complements our existing partnerships in Taiwan, Hong Kong, the Middle East, and Mexico, further strengthening our international commercialisation framework."

"The impressive growth trajectory of India's nerve repair market aligns perfectly with our strategic vision to provide innovative nerve repair solutions to surgeons and patients worldwide. We believe the NervAlign® technology is particularly well-suited to address the specific needs of the Indian healthcare system, offering a cost-effective solution with demonstrable clinical benefits."

About the NervAlign Nerve Cuff

ReNerve’s NervAlign® Nerve Cuff is a bioabsorbable medical device designed to support and protect nerves during the healing process following peripheral nerve injury or surgical repair. The device is naturally absorbed by the body within six months, leaving only regenerated nerve tissue. Its versatility makes it suitable for use across a wide range of nerve surgery procedures and medical specialties​.

For Further Information...

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
[email protected]

Jane Morgan
Investor & Media Relations
Jane Morgan Management
[email protected]

About ReNerve Limited

ReNerve Limited (ASX: RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry’s Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff.

For more information, visit: www.renerve.com.au

Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]